Bcl-2 oncogene expression in estrogen receptor-positive and negative breast carcinoma

Purpose: The aim of this study was to evaluate Bcl-2 oncogene expression in estrogen receptor (ER)-positive and negative breast carcinomas. Methods: A Study involving 72 cases of infiltrating ductal carcinoma of the breast in postmenopausal women divided into two groups: Group A (ER positive, n = 37) and Group B (ER negative, n = 35). Immunohistochemical analysis of bcl-2 expression was carried out semiquantitatively based on the percentage of stained tumoral cells and the intensity of staining. The chi-square test was used in the statistical analysis of the data and significance was established at p < 0.05. Results: Bcl-2 oncogene expression was statistically greater in tumors of Group A (59.5%) compared to those of Group B (8.6%), (p < 0.001). Conclusion: Bcl-2 had a significantly greater expression in the ER-positive breast tumors compared to ER-negative tumors.

Breast; Cancer; Apoptosis; Estrogen receptor; Bcl-2

[1] Simpson P.T., Reis-Filho J.S., Gale T., Lakhani S.R.: “Molecular evolution of breast cancer”. J. Pathol., 2005, 205, 248.

[2] Allred D.C., Harvey J.M., Berardo M., Clark G.M.: “Prognostic and predictive factors in breast cancer by immunohistochemical analysis”. Mod. Pathol., 1998, 11, 155.

[3] Teixeira C., Reed J.C., Pratt M.A.: “Estrogen promotes chemotherapeutic drug resistance by a mechanism involving bcl-2 protooncogene expression in human breast cancer cells”. Cancer Res., 1995, 55, 3902.

[4] Putti T.C., El-Rehim D.M., Rakha E.A., Paish C.E., Lee A.H., Pinder S.E. et al.: “Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis”. Mod. Pathol., 2005, 18, 26.

[5] Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M. et al.: “Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999”. Arch. Pathol. Lab. Med., 2000, 124, 966.

[6] Krajewski S., Thor A.D., Edgerton S.M., Moore D.H. 2nd, Krajewska M., Reed J.C.: “Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers”. Clin. Cancer Res., 1997, 3, 199.

[7] Dowsett M., Archer C., Assersohn L., Gregory R.K., Ellis P.A., Salter J. et al.: “Clinical studies of apoptosis and proliferation in breast cancer”. Endocr. Relat. Cancer, 1999, 6, 25.

[8] Tan P.H., Bay B.H., Yip G., Selvarajan S., Tan P., Wu J. et al.: “Immunohistochemical detection of Ki-67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death”. Mod. Pathol., 2005, 18, 374.

[9] Johnston S.R., MacLennan K.A., Sacks N.P., Salter J., Smith I.E., Dowsett M.: “Modulation of Bcl-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen”. Eur. J. Cancer, 1994, 30A, 1663.

[10] Lee H.D., Koo J.Y., Jung W.H.: “Correlations of Bcl-2 expression with clinicopathological features in breast cancer”. Yonsei Med. J., 1997, 38, 206.

[11] van Slooten H.J., Clahsen P.C., van Dierendonck J.H., Duval C., Pallud C., Mandard A.M. et al.: “Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy”. Br. J. Cancer, 1996, 74, 78.

[12] Jalava P., Kuopio T., Huovinen R., Laine J., Collan Y.: “Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints”. Anticancer Res., 2005, 25, 2535.

[13] Elston C.W., Ellis I.O., Goulding H., Pinder S.E.: “Role of pathology in the prognosis and management of breast cancer”. In: Elston C.W. & Ellis I.O. (eds.): “The Breast”. Edinburgh, Scotland, Churchill Livingstone 1998, 385.

[14] Hlupic L., Jakic-Razumovic J., Bozikov J., Coric M., Belev B., Vrbanec D.: “Prognostic value of different factors in breast carcinoma”. Tumori, 2004, 90, 112.

[15] Gerdes J., Li L., Schlueter C., Durchrow M., Wohlenberg C., Gerlach C. et al.: “Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67”. Am. J. Pathol., 1991, 138, 867.

[16] Bozzetti C., Nizzoli R., Naldi N., Guazzi A., Camisa R., Bella M.A. et al.: “Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors”. Cancer, 1999, 87, 224.

[17] Bilalovic N., Vranic S., Hasanagic S., Basic H., Tatarevic A., Beslija S. et al.: “The Bcl-2 protein: a prognostic indicator strongly related to ER and PR in breast cancer”. Bosn. J. Basic Med. Sci., 2004, 4, 5.

[18] Hellemans P., van Dam P.A., Weyler J., van Oosterom A.T., Buytaert P., Van Marck E.: “Prognostic value of bcl-2 expression in invasive breast cancer”. Br. J. Cancer, 1995, 72, 354.

[19] Lee K.H., Im S.A., Oh D.Y., Lee S.H., Chie E.K., Han W. et al.: “Prognostic significance of bcl-2 expression in Stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy”. BMC Cancer, 2007, 12, 7.

[20] da Silva B.B., Lopes I.M., Gebrim L.H.: “Effects of raloxifene on normal breast tissue from premenopausal women”. Breast Cancer Res. Treat., 2006, 95, 99.